WebJan 27, 2015 · Lund, Sweden, 2015-01-27 08:23 CET (GLOBE NEWSWIRE) -- Two clinical studies on EXINI’s imaging biomarker BSI (Bone Scan Index) have been approved for the 2015 American Society of Clinical ... WebMay 4, 2024 · Lantheus Holdings subsidiary EXINI Diagnostics has secured CE mark approval for its artificial intelligence (AI) based and deep learning-enabled medical device software called aPROMISE. The software helps healthcare professionals and researchers conduct quantitative assessment of prostate-specific membrane antigen (PSMA) PET/CT …
Prospective evaluation of computer-assisted analysis of skeletal ...
WebApr 10, 2024 · Breast cancer and prostate cancer are sex hormone-dependent cancers, and estrogen or androgen suppression therapy is the standard treatment. Cancer treatment-induced bone loss (CTIBL): bone loss and osteoporosis have become important side effects of these therapies. To summarize the current evidence … WebAug 20, 2012 · The software EXINI bone™, which provides valuable clinical information in prostate and breast cancer, has received FDA approval. This announcement... Breakthrough for EXINI, FDA approval for ... ingyenes iratminta
Cancer Spread to Bones: Life Expectancy, Treatment, Types - Healthline
WebBackground: The Zeus/SPCG11 study is a randomized controlled clinical trial with the aim to assess the efficacy of zoledronic acid (ZA) in preventing bone metastases in high-risk prostate cancer (PCa) patients. Bone Scan Index (BSI) reflects the tumour burden in bone calculated from bone scintigraphy, and has recently been validated as an imaging … WebBSI may be a valuable method of complementing treatment response evaluation in patients with advanced prostate cancer. An increase in Bone Scan Index (BSI) was associated with shorter time to disease progression in patients treated with ODM-201. ... We used the automated EXINI bone BSI software (EXINI Diagnostics AB, Lund, Sweden) to obtain … m john photography